natgillin/translations-raw huggingface dataset:
2.00E-04 2.11E-10 A bispecific antibody or antibody fragment thereof that specifically binds to IL-13 and IL-4, wherein the bispecific antibody or antibody fragment thereof contains two light chains with the structure N-VLhB-B13-inker-VLh8D4-8-CL-C and two heavy chains with the structure N-VHhB-B13-linker-VHh8D4-8-CH1-CH2-CH3-C, wherein CL is the light chain constant region, VLhB-B13 is a humanized light chain variable domain of anti IL-13 antibody B-B13, YLh8D4-8 is a humanized light chain variable domain of anti IL-13 antibody B-B13, VHhB-B13 is a humanized heavy chain variable domain of anti IL-13 antibody B-B13, and VHh8D4-8 is a humanized heavy chain variable domain of anti IL-4 antibody 8D4-8. 
Bispecifično antitijelo ili njegov bispecifični fragment antitijela koji se specifično veže na IL-13 1 IL-4, naznačeno time da navedeno bispecifično antitijelo ili njegov bispecifični fragment antitijela sadrži dva laka lanca sa strukturom N-VLyB-Bi3-poveznica-VLyppp4.g-CL-C i dva teška lanca sa strukturom N-VHlip.Bi3-poveznica-V Hypp4-g-CH1-CH2-CH3-C, pri čemu VLip-pi3 sadrži sekvencu aminokiseline SEQ ID NO: 1, pri čemu VLyppa.g sadrži sekvencu aminokiseline SEQ ID NO: 3, pri čemu VHip.pi3 sadrži sekvencu aminokiseline SEQ ID NO: 2, pri čemu VHhipna-s sadrži sekvencu aminokiseline SEQ ID NO: 4, te pri čemu svaka poveznica je peptidna poveznica koja ima sekvencu aminokiseline koja sadrži SEQ ID NO: 6.
The antibody or binding fragment thereof of claim 24, wherein the B cell proliferative disorder is selected from lymphoma, non-Hogkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma. 
Farmaceutski sastav prema zahtjevu 16 za uporabu prema zahtjevu 17, naznačen time, da je proliferativni poremećaj B-stanice odabran od sljedećih: limfom, non-Hodgkinov limfom (NHL), agresivni NHL, recidivni agresivni NHL, recidivni indolentni NHL, otporan NHL, otporan indolentni NHL, kronična limfocitna leukemija (CLL), mali limfocitni limfom, leukemija, leukemija kosmatih stanica (HCL), akutna limfocitna leukemija (ALI), limfom plaštenih stanica.
The compound or a salt thereof according to any one of claims 1 to 11, wherein X2 is a group represented by general formula [3]: wherein X2a represents an optionally substituted C1-5 alkylene group, provided that X2a is bonded to Y1. The compound or a salt thereof according to any one of claims 1 to 11, wherein X2 is a group represented by general formula [4]: wherein X2a represents an optionally substituted C1-5 alkylene group, provided that X2a is bonded to Y1. 
Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da je X2 skupina predstavljena općom formulom [4]: pri čemu X2a predstavlja po izboru supstituiranu C1-5 alkilensku skupinu, pod uvjetom da je X2a vezan na Y1; pri čemu su supstituenti za C1-5 alkilensku skupinu od X2a definiranu kao što je definirano u patentnom zahtjevu 1.
Due to the second guiding passage, the surgeon only has to look at the screen and not on the endoscopic equipment, as the passage guides e.g. the needle. 
Zbog drugog prolaza za vođenje, kirurg treba samo pogledati na ckran i ne na cndoskopsku opremu da vidi kako sc kroz prolaz vodi, na primjcr, igla.
at least one support device for at least one person which is suspended from the carrier at a distance from the axis of rotation, wherein the support device is rotatable respect to the carrier about an axis of rotation which runs parallel to the axis of rotation of the carrier and about an axis of rotation which runs transverse to the axis of rotation of the carrier and crosses the axis of rotation of the carrier. 
Uređaj za zabavu prema bilo kojem od prethodnih zahtjeva, gdje je izvedena najmanje jedna balansirajuća poluga koja je pričvršćena za najmanje jednu oscilirajuću polugu (5), gdje je na slobodnom kraju balansirajuće poluge izvedena masa, i gdje je balansirajuća poluga izvedena na strani osi (4) rotacije koja je nasuprot strani gdje je smještena oscilirajuća poluga (5).
water situated over said edge zone (15) and said wave progression zone (16); 
– vodu koja se nalazi preko navedenog rubnog područja (15) i navedenog područja napredovanja valova (16);
an antisense oligomer which has a nucleotide sequence having at least 80% identity with a nucleotide sequence of SEQ ID NO: 1 or 2 and has an activity to cause skipping of the 51st exon in the human dystrophin gene; and 
antisensni oligomer koji ima nukleotidnu sekvencu koja ima najmanje 80% istovjetnosti s nukleotidnom sekvencom SEQ ID NO: 1 ili 2 i ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu.
A shaking device according to claim 1, wherein two support bodies are provided movably mounted to the holding rod and oscillating in a same direction or in opposite directions. 
Vibrirajući uređaj prema zahtjevu 1, pri čemu su dva elementa koji služe kao oslonci fleksibilno spojena sa šipkom koja ih drži te vibriraju u istom ili suprotnom smjeru.
Also, the base 110 is coupled to the container 106 by a screw-fit relation. 
Također, postolje 110 je spojeno na posudu 106 preko navoja.
have a reduction in unsulfated iduronic and/or glucuronic acid units when compared to native heparin; wherein the predominant disaccharide of the polysaccharide is a disaccharide having the chemical structure: wherein R' is a threonate residue; and n is an integer of from 2 to 25, such that it comprises from 2 to 25 disaccharide units corresponding to molecular weights from 1.2 to 15 kDa; and wherein the chemically modified heparin has, in a 1H-NMR spectrum, no unidentified signals in the ranges 0.10-2.00 ppm, 2.10-3.10 ppm and 5.70-8.00 ppm larger than 4 per cent when compared to the height of the signal present in native heparin at 5.42 ppm. 
(ili) imaju redukciju u jedinicama nesulfatizirane iduronske i/ili glukuronske kiseline kada se uspoređuje s prirodnim heparinom; pri čemu je prevladavajući disaharid polisaharida disaharid koji ima kemijsku strukturu: pri čemu R' je treonatni ostatak; i n je cijeli broj od 2 do 25, tako da sadrži 2 do 25 disaharidnih jedinica koje odgovaraju molekularnim masama od 1,2 do 15 kDa; i pri čemu kemijski modificiran heparin nema, u 'H- NMR spektru, neidentificirane signale u rasponu od 0,10-2,00 ppm, 2,10-3,10 ppm i 5,70-8,00 ppm veće od 4 posto kada se uspoređuje s visinom signala prisutnog u prirodnom heparinu na 5,42 ppm.
continuously acquiring and recording, by a plurality of measurement stations equipped with vibroacoustic sensors discretely located along the pipeline, of vibroacoustic signals due to the vibrations generated by contact/friction of the pig device with the welding seams of the pipeline and/or with other physical variations locally present in multiple pipe sections of the pipeline; 
- kontinuiranog dobivanja i snimanja, uz pomoć više mjernih postaja (14), opremljenih vibroakustičnim senzorima, postavljenim pojedinačno po cjevovodu (12), vibroakustičnih signala nastalih zbog tranzijenata hidrauličnog tlaka, ifili zbog vibracija koje generira prasica koja se kreće (10) u koracima kontakta odnosno trenja na varnim šavovima, i/ili zbog drugih fizičkih varijacija prisutnih lokalno u više cijevnih odjeljaka cjevovoda (12);
The 3,11b- cis -dihydrotetrabenazine used in the invention may be in substantially pure form, for example at an isomeric purity of greater than 90%, typically greater than 95% and more preferably greater than 98%. 
3,11b, cis-dihidrotetrabenazin koji se koristi u izumu može biti u jako čistom obliku, na primjer izomerne čistoće veće od 90%, uobičajeno je veće od 95% 1 najpovoljnije je veće od 98%.
An isolated host cell or non-human host organism containing a nucleotide sequence according to claim 9 . A pharmaceutical composition containing an antibody according to claim 1 in association with a pharmaceutically acceptable thinner or carrier. 
Stanica domaćin ili neljudski organizam domaćin, naznačen time što sadrži nukleotidni slijed u skladu s patentnim zahtjevom 9 ili vektor u skladu s patentnim zahtjevom 10.
The present invention relates to the use of polymer dispersions for dust control, wherein these polymer dispersions can be obtained by radically initiated emulsion polymerisation of the components a to e: a. 
Korištenje polimerne disperzije kao agensa za kontrolu prašine, naznačeno time da se disperzija polimera može dobiti polimerizacijom emulzije komponenata od a do e, koju pokreću slobodni radikali, gdje su: a.
They may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. 
To mogu biti vodene otopine koje, primjerice, sadrže polioksietilen-9-lauril-eter, glikokolat i deoksikolat, ili uljne otopine namijenjene primjeni u obliku kapi za nos, ili u obliku gela za intranazalnu primjenu.
The container according to claim 5, wherein the further recess (21) is delimited by a receding section (22) of the carrier (5). 
Spremnik u skladu s patentnim zahtjevom 6, naznačen time što dodatni otvor (21) je oivičen uvučenim dijelom (22) nosača (5).
A sealed package comprising the pharmaceutical composition of any one of claims 1-8. The sealed package of claim 10, further comprising a desiccant. 
Čvrsto zatvoreno pakiranje, naznačeno time, da sadrži farmaceutski sastav prema jednom od patentnih zahtjeva 1-8.
at a temperature below 40° C., in the presence of a non-nucleophilic base, to produce a benzyl amide derivative of the formula (IV) of enantiomeric purity higher than 95%; and 
na temperaturi ispod 40? €, u prisutnosti ne-nukleofilne baze, za proizvodnju benzil amid derivata formule (IV) enantiomerske čistoće veće od 95%; 1
Thus Step B of the above-mentioned method is preferably carried out with EDC x HCI as coupling agent (without HOBT) in THF / NMP solvent mixtures having a ratio of 10: 1 to 1:1. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu se korak 8 izvodi s EDC x HCI kao reagensom povezivanja u smjesi otapala THF/NMP.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound fluopyram. 
spoja formule (I) [image] naznačen time da R1 je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i spoj mandipropamid.
A process for the preparation of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, which comprises reaction of an acid of Formula (II) with (S)-3-amino-3-(4-chlorophenyl)propan-1-ol: 
Postupak za pripravu spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time da postupak sadrži reakciju kiseline Formule (II) i (S)-3-amino-3-(4-klorofenil)propan-1 -ola:
Method according to claim 4, wherein said direct flow drilling mode (F 1) coming from said second auxiliary chamber (7) is transmitted to said first auxiliary chamber (6), and subsequently sent to said string of drill rods (17). 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što se bušaći protok (F1), koji dolazi iz druge pomoćne komore (7) prebacuje u prvu pomoćnu komoru (6), a odatle se zatim šalje u niz bušaćih šipki (17).
An important characteristic of the light stabilising composition according to the invention is its relatively high absorption of UV light in the range of 250-400 nm and especially in the range of 250-350 nm. 
Važna karakteristika pripravka za stabiliziranje na svjetlo prema izumu je njegova relativno visoka apsorpcija UV svjetla u opsegu od 250-400 nm i naročito u opsegu od 250-350 nm.
wherein the pieces (2) of fabric forming the garment are joined by a chain stitch seam using polyester thread (4), and wherein the content of polyurethane covering the synthetic fibres is in the range of 0.1% and 0.3% in weight. 
Å ivanje navedenih različitih dijelova u cjelinu korištenjem igala s okruglim vrhom za šav sa lančanim ubodom i sto postotnog poliesterskog konca za oblikovanje odjevnog predmeta, - pranje odjevnog predmeta, i - dodavanje poliuretana i polietilena tijekom koraka pranja, za zaštitu sintetičkih vlakana odjevnog predmeta.
R1d and R1e are independently a hydrogen atom, a halogen atom, a cyano group, a hydroxyl group, a lower alkyl group or a hydroxy-lower alkyl group, or together form a lower alkylene group wherein one or two or more methylene groups constituting the lower alkylene group may be independently replaced by an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, a carbonyl group, a vinylene group or a group of-N(R1f)-, and/or substituted by a hydroxyl group or a lower alkyl group; 
d i R1e su nezavisno atom vodika, halogen atom, cijano skupina, hidroksil skupina, niža alkilna skupina ili hidroksi-niža alkilna skupina, ili zajedno formiraju nižu alkilen skupina gdje jedna ili više metilenskih skupina koje čine nižu alkilen skupinu mogu nezavisno biti zamijenjene atomom kisika, atomom sumpora, sulfinil skupinom, sulfonilom skupinom, karbonil skupinom, vinilen skupinom ili skupinom -N(R1f)-, i/ili supstituirane hidroksil skupinom ili nižom alkilnom skupinom;
Salts of the compounds of the formula I are preferably agriculturally acceptable salts. 
Spojevi formule I prema patentnom zahtjevu 1 koja su izabrani iz slijedećeg popisa:
FIG. 9 is a schematic partial section of the discharge device with the metered dose valve according to the second embodiment of the present invention in the intermediate position; and 
prikazuje shematski djelomičan presjek naprave za pražnjenje s ventilom za odmjeravanje doze prema drugoj izvedbi predloženog izuma u međupoložaju; i slika 10 prikazuje shematski djelomičan presjek naprave za pražnjenje s ventilom za odmjeravanje doze prema drugoj izvedbi predloženog izuma u drugom položaju.
The compound according to claim 20, wherein Cy3 represents a cycloalkyl group, an aryl group or a heteroaryl group. 
Spojevi u skladu s patentnim zahtjevom 20, naznačeni time, da Cy3 predstavlja cikloalkilnu skupinu, arilnu skupinu ili heteroarilnu skupinu.
A suitable method for determining the colour intensity at 610 nm is described below. 
Odgovarajući postupak za određivanje intenziteta boje pri 610 nm je opisan niže u tekstu. HR P20070273 T3
wherein R3, E, R12 and R1 are as defined above, or a pharmaceutically acceptable salt thereof. Pharmaceutical Formulations 
o la) pri čemu R*, E, R'*i R' su kako je gore definirano, ili njegova farmaceutski prihvatljiva sol.
The formulation according to claim 4, in the form of capsules or tablets. 
Formulacija u skladu sa patentnim zahtjevom 3, u obliku kapsula ili tableta.
deprotecting the boronic acid moiety to form the compound of formula (XIV) or a boronic acid anhydride thereof. 
(h) deprotekcija grupe organoborne kiseline da bi se formirao spoj formule (XTV) ili njegov anhidrid organoborne kiseline.
The process of claim 7, where the chiral acid is tartaric acid or mandelic acid. The process of claim 9, wherein the chiral acid is L-tartaric acid or D-mandelic acid. 
Postupak prema zahtjevu 5, naznačen time da je kiralna kiselina vinska kiselina ili mandelinska kiselina, posebno L-vinska kiselina ili D-mandelinska kiselina.
Use according to any one of the preceding claims, characterized in that said 2-((1-methylpropyl)amino)ethanol is added to said suspension in an amount of from 500 to 15000 mg, preferably of from 1000 to 5000 mg, and more preferably of 1300 to 2000 mg, per liter of the aqueous phase of said suspension. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da je navedeni 2-((1- metilpropil)amino)etanol dodan u navedenu otopinu u količini od 1000 do 5000 mg, poželjnije od 1300 do 2000 mg, po litri vodene faze navedene otopine.
Therefore, a part of the tumor-associated antigens identified according to the invention which corresponds to the non-transmembrane portion, in particular the extracellular portion of the tumor-associated antigens or is comprised thereof, or a corresponding part of the nucleic acids coding for the tumor-associated antigens identified according to the invention is preferred for therapy and/or prophylaxis. 
Farmaceutska kompozicija prema patentnom zahtjevu 1 za uporabu u postupku za liječenje ili prevenciju kancera naznačenog ekspresijom antigena povezanog sa tumorom prema patentnom zahtjevu 1, gdje je antitijelo monoklonalno, himerno ili humanizirano antitijelo, 1li je fragment antitijela.
the binder is polyethylene glycol or polyvinylpyrrolidone, or a combination thereof, and is present at a concentration of about 5% to about 15% (w/w); 
Cc) vezivo je polietilenglikol ili polivinilpirolidon, ili njihova kombinacija, i prisutno je u koncentraciji od oko 5% do oko 15% (masa/masa);
The pharmaceutical composition for use according to claim 11, wherein the disease, infection, and/or other condition is C. difficile -associated diarrhea (CDAD). 
Farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 11, pri čemu je bolest, infekcija i/ili drugo stanje dijareja povezana s Ć. difficile (CDAD).
A pyrido(2,3-d)pyrimidine derivative having the general formula: wherein: 
PATENTNI ZAHTJEVI Derivat pirido(2,3-d)pirimidina koji ima opću formulu:
The method as in claim 1, wherein the feeding steps respectively comprise continuously feeding the predispersion and the remaining portion of the viscous material into the first container; and the method further comprises intermittently or continuously removing a reaction product thereof from the first container. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da koraci dodavanja redom sadrže kontinuirano dovođenje predisperziju i preostali dio viskoznog materijala u prvi spremnik; a navedeni postupak dodatno obuhvaća povremeno ili kontinuirano uklanjanje njegovog reakcijskog proizvoda iz prvog spremnika.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound fludioxonil. 
CH naznačen time da je R; difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj fludioksonil.
The pharmaceutical composition for use according to claim 18, wherein said inflammatory bowel disease is selected from the group consisting of Crohn's disease and ulcerative colitis. 
Farmaceutski sastav u skladu s patentnim zahtjevom 12, pri čemu je navedena upalna bolest crijeva odabrana iz grupe koja se sastoji od Chronove bolesti i ulceroznog kolitisa.
Use according to any one of claims 16 to 19, wherein the fluid provided via the lance tube has a flow rate of from about 0.05 l/min to about 5 l/min, preferably of from about 0.1 l/min to about 41/min, more preferably of from about 0.191/min to about 2.7 l/min. 
Uporaba prema bilo kojem od zahtjeva 16 do 19, naznačena time da fluid doveden putem dugačke cijevi ima protok od oko 0.05 I/min do oko 5 Y/min, poželjno od oko 0.1 l/min do oko 4 I/min, poželjnije od oko 0.191/min do oko 2.7 I/min.
A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. 
Kruta podloga može biti jedna ili više supstanci koje mogu također imati ulogu kao sredstva za razrijeđivanje, kao korigens okusa, za povećanje topivosti, kao lubrikant, kao sredstvo za suspenziranje, kao vezivo, kao konzervans, kao sredstvo za raspadanje tableta ili materijal za kapsuliranje.
A method according to claim 62 wherein the composition is administered 7 days or less prior to harvest. 
Metoda temeljem zahtjeva 62 gdje je sastav primijenjen 7 dana ili manje prije berbe.
In an embodiment of the invention there is provided a mushroom production process comprising the step of, after removing the spent mushroom compost from the mushroom growing shed, delivering the spent mushroom compost to a fuel storage area for subsequent combustion. 
Postupak sukladno bilo kojem od prethodnih Zahtjeva koji sadrži korak u kojem se, nakon uklanjanja komposta od korištenih gljiva iz prostora za uzgoj gljiva (3), kompost od korištenih gljiva dostavlja u prostor za skladištenje goriva (7) radi kasnijeg spaljivanja.
Speed by volume of the fluidization air was kept at 60 m3/hour in the first 15 minutes of the pelletization and later at 90 m3/hour. 
Volumna brzina zraka za fluidiziranje održavana je na 60 mVsat tijekom prvih 15 minuta granuliranja i nakon toga na 90 m*/sat.
calculating the percentage of brominated tyrosine in the glatiramer acetate. The subject invention also provides a process for preparing a pharmaceutical composition containing a mixture of polypeptides which do not all have the same amino acid sequence, where each polypeptide consists of glutamic acid, alanine, tyrosine and lysine, wherein the mixture has a predetermined percentage of brominated tyrosine acceptable for inclusion in a pharmaceutical composition, which comprises obtaining a batch of a mixture of polypeptides having nonuniform amino acid sequences, where each polypeptide consists of glutamic acid, alanine, tyrosine and lysine; 
Postupak za pripremanje farmaceutskog sastava koji sadrži glatiramer acetat, naznačen time, da glatiramer acetat ima predodređeni postotak bromiranog tirozina, prihvatljivog za uključivanje u farmaceutski sastav, koji postupak sadrži dobivanje šarže glatiramer acetata; mjerenje postotka bromiranog tirozina šarže postupkom koji sadrži a) hidroliziranje šarže da se dobije hidrolizat; b) eluiranje hidrolizata preko kromatografske kolone;
The method of claim 1, wherein the antibody comprises a VH sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 54, 58, or 62. 
SEKVENCE: 54 te VL sekvencu koja ima najmanje 95% identiteta aminokiselinskog slijeda IDENTIFIKACIJSKOG BR. SEKVENCE: 34; ili b) VH sekvencu koja ima najmanje 95 % identiteta aminokiselinskog slijeda IDENTIFIKACIJSKOG BR.
Use of (a) a PDE4 inhibitor for the preparation of a medicament, for simultaneous, concurrent, separate or sequential use in combination with (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the treatment of a respiratory disease which responds to M3 antagonism in a patient. 
Uporaba (a) kortikosteroida kako je definirano u patentnim zahtjevima 1 i 3 do 6, naznačena time, da je za pripravu lijeka za istovremenu, istodobnu, odijeljenu ili uzastopnu uporabu u kombinaciji s (b) antagonistom M3 muskarinskih receptora kako su definirani u patentnom zahtjevu 1 ili 2 za liječenje dišnih bolesti kako su definirane u patentnom zahtjevu 10 ili 11. t>&
communicating the measured frequency characteristic measured in the area associated with the second group of power units to the measurement system; 
prenošenje frekvencijske karakteristike izmjerene u području povezanom s drugom skupinom mrežnih uređaja (119) do mjernog sustava;
The frame is made of plastic and the sheath is made of a suitable flexible material, such as paperboard, as it forms part of a hinge that requires high flexibility. 
Okvir je načinjen od plastike, a korice su načinjene od prikladnog savitljivog materijala, takvog kao što je karton, budući da taj materijal čini dio panta što zahtijeva veliku savitljivost.
The compound of claim 19, wherein said compound is 3-(2,4-dihydroxy-5-isopropylphenyl)-4-(N-methyl-indol-5-yl)-5-mercapto-[1,2,4]triazole, or a tautomer, pharmaceutically acceptable salt, solvate, or clathrate thereof. 
HR P20130095 T1 Spoj prema zahtjevu 19, pri čemu je navedeni spoj3-(2,4-dihidroksi-5-izopropilfenil)-4-(N-metil-indol-5-i1)-5- merkapto-[1,2,4]triazol, ili njegov tautomer, farmaceutski prihvatljiva sol, solvat ili klatrat.
The method of claim 1, 4-5, and 7 wherein the formation systems are pulsed power formation systems. 
Sustav prema zahtjevu 1, 4 do 5 i 7, naznačen time, da tvorbeni sustavi su pulsirajući strujni tvorbeni sustavi.
treating said patient with said specific binding member if the average HER2 gene copy number is greater than or equal to 10 per tumour cell. 
(ii) liječenje spomenutog pacijenta s navedenim specifičnim veznim elementom ako je prosječan broj genskih kopija od HER2 veći od 10 1li je točno 10 po stanici tumora.